Skip to main content

Experts stress on predictable regulatory environment to create global trust in India as a stable clinical trial market

Experts in the clinical trial arena are of the view that there is an urgent need for a predictable regulatory environment in the country to create global trust in India as a stable clinical trial market. But, they rued that developments in the last few years have dented the confidence of sponsors in doing clinical research in India. 

India is on a slow recovery period and there is a need to ensure that it continues the growth trajectory.

"Various factors, including reports of alleged irregularities in clinical trials have also led to a lot of misinformation and negative perceptions of clinical trials in India. Besides this, some of the clauses of The Draft Clinical Trial Rules 2018 around compensation are regressive and, if implemented, could force sponsors  both domestic and foreign to reconsider doing clinical trials in India,"explains Naz Haji, Managing Director, IQVIA India. 

Formed through the merger of IMS Health and Quintiles, IQVIA is a leading global provider of information, innovative technology solutions and contract research services.

Echoing similar views, experts pointed out that India is still recovering from the setback of 2013 and any further setback will hurt country's image further and seriously impact ability to attract clinical research into the country, besides denying patients access to the latest treatment options. Regulators should have more consultative meetings with stakeholders to review these contentious clauses, while ensuring that patient safety, confidentiality and quality are not compromised. 


Comments

Popular posts from this blog

Isotretinoin in India: A tragedy in the offing

Isotretinoin in India: A tragedy in the offing Wednesday, March 28, 2007 08:00 IST  Seema Thakral Isotretinoin is the drug of choice for severe calcitrant cystic acne vulgaris, which often causes scarring and depression from disfigurement. Isotretinoin has been called "the greatest medical advance of the 1980's." A majority of patients with acne are permanently cleared after a four to five months course of treatment. It has also been used off-label for a variety of oncology uses including: cervical cancer, head and neck cancer, squamous cell cancer of the skin, juvenile chronic myelogenous leukemia (CML), and neuroblastoma. However, the drug is a proved teratogen and carries a significant risk of birth defects, if it taken during pregnancy. Birth defects, which have been documented following isotretinoin exposure include abnormalities of the face, eyes, ears, skull, central nervous system, cardiovascular system, and thymus and parathyroid glands. There is an increased ris

Contract Research Organization Services (CROs) Market Worth 56.34 Billion USD by 2023

 According to a new market research report "Contract Research Organization Services (CROs) Market by Type (Discovery, CMC, Preclinical, Clinical Research, Laboratory Services), Therapeutic Area (Oncology, CNS, Cardiovascular), End User (Pharmaceuticals & Medical Device) - Global Forecast to 2023", published by MarketsandMarkets™, the global market is projected to reach USD 56.34 Billion by 2023 from USD 39.13 Billion in 2018, at a CAGR of 7.6%. Continue reading here ᐧ

The Connection Between Sedatives and Fractures in Elderly Patients

Johns Hopkins Health Alerts: Prescription Drugs The Connection Between Sedatives and Fractures in Elderly Patients All drugs have potential side effects. Indeed, at some point you've probably squinted down the laundry list of possible side effects on the package insert of your medications. Common drug-related side effects include blurred vision, drowsiness, dizziness, dry mouth, heart palpitations, erectile dysfunction, memory impairment, and nervousness. Fortunately, many of these drug side effects occur in only small numbers of people. Now researchers have called into question the connection between sedatives which can cause dizziness and the potential for falls in elderly patients. They point out that well-meant policies discouraging sedative use in older people to prevent falls and fractures may not be necessary. Starting in 1989, New York State required doctors to fill out prescriptions in triplicate for benzodiazepines, the most widely used class of sedativ